| Greg D Stewart, MS | |
|
1200 E Michigan Ave, Suite330, Lansing, MI 48912-1800 | |
| (517) 364-5678 | |
| (517) 364-5674 |
| Full Name | Greg D Stewart |
|---|---|
| Gender | Male |
| Speciality | Audiologist |
| Location | 1200 E Michigan Ave, Lansing, Michigan |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639182793 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | GS000118 (Michigan) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Greg D Stewart, MS 1701 Lake Lansing Rd, Suite 100, Lansing, MI 48912-3798 Ph: (517) 485-0001 | Greg D Stewart, MS 1200 E Michigan Ave, Suite330, Lansing, MI 48912-1800 Ph: (517) 364-5678 |
News Archive
Huntington's disease (HD) is an incurable and fatal hereditary disease. Developing disease-modifying drugs to treat patients with HD depends on studying them in animal models. Scientists evaluated the mouse models used for developing new treatments for mood disorders in HD and recommended which of these models are most relevant to their studies.
Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have discovered that a protein, zyxin, is necessary for the maintenance and repair of the cell's cytoskeleton, or internal framework, which serves as the muscle and bone of the cell. The research has implications for cancer, as well as other diseases, since alterations in the cytoskeleton are often associated with disease. The research was published in the Sep. 14, 2010, issue of the journal Developmental Cell.
Researchers have demonstrated the potential to engineer brown adipose tissue, which has therapeutic promise to treat metabolic diseases such as obesity and type 2 diabetes, from white adipose-derived stem cells.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that in the Phase 3 VIVID-DME and VISTA-DME trials of EYLEA (aflibercept) Injection for the treatment of diabetic macular edema, EYLEA 2 milligrams (mg) dosed monthly and EYLEA 2 mg dosed every two months (after 5 initial monthly injections) achieved the primary endpoint of a significantly greater improvement in best-corrected visual acuity from baseline compared to laser photocoagulation at 52 weeks.
› Verified 2 days ago
Dr. Brooke Marie Tudor, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 1200 E Michigan Ave, Suite 330, Lansing, MI 48912 Phone: 517-364-5678 | |
Audiology And Hearing Services Llc Audiologist Medicare: Medicare Enrolled Practice Location: 6512 Centurion Dr, Suite 340, Lansing, MI 48917 Phone: 517-323-6222 Fax: 517-323-6279 | |
Lisa M Holcomb, Audiologist Medicare: Not Enrolled in Medicare Practice Location: 1200 E Michigan Ave, Suite 330, Lansing, MI 48912 Phone: 517-364-5678 Fax: 517-364-5674 | |
Dynamic Audiology Inc Audiologist Medicare: Not Enrolled in Medicare Practice Location: 3410 Belle Chase Way, Suite 700, Lansing, MI 48911 Phone: 517-887-7660 Fax: 517-887-7661 | |
Martin James Mahoney, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 310 N Clippert St, Ste 4, Lansing, MI 48912 Phone: 517-322-1691 Fax: 517-324-0210 | |
Kathryn E Debler, AUDIOLOGIST Audiologist Medicare: Medicare Enrolled Practice Location: 6512 Centurion Dr, Suite 340, Lansing, MI 48917 Phone: 517-323-6222 Fax: 517-323-6279 |